{"disease":{"id":"smoldering-plasma-cell-myeloma","name":"smoldering plasma cell myeloma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05136807","title":"Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03937635","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":288,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT02726750","title":"Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05312255","title":"Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma","phase":"NA","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT04776395","title":"Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT02960555","title":"Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03631043","title":"Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05014646","title":"Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":27,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT02603887","title":"Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT05288062","title":"Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT04370483","title":"Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03952832","title":"Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"City of Hope Medical Center","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}